Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE-/- mice with or without diabetes

Cardiovascular Research

Volumn 104, Issue 1, 2014, Pages 160-170

  Hanssen, Nordin M J ^a,b   Brouwers, Olaf ^a,b   Gijbels, Marion J ^a,b,c   Wouters, Kristiaan ^a,b   Wijnands, Erwin ^a,b   Cleutjens, Jack P M ^a,b   De Mey, Jo G ^a,d   Miyata, Toshio ^e   Biessen, Erik A ^a,b   Stehouwer, Coen D A ^a,b   Schalkwijk, Casper G ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; Atherosclerosis; Diabetes

Indexed keywords

3 DEOXYGLUCOSONE; ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN E; GAMMA INTERFERON; GLUCOSE; GLYOXAL; GLYOXALASE; GLYOXALASE 1; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; KELCH LIKE ECH ASSOCIATED PROTEIN 1; KERATINOCYTE DERIVED CHEMOKINE; LEPTIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE; GLO1 PROTEIN, HUMAN; LACTOYLGLUTATHIONE LYASE; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GLYCATION; INFLAMMATION; INSULIN BLOOD LEVEL; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; THORACIC AORTA; VASODILATATION; ANIMAL; AORTA DISEASE; ATHEROSCLEROTIC PLAQUE; BLOOD; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; COMPARATIVE STUDY; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TRANSGENIC MOUSE; UPREGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA, THORACIC; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELLS, CULTURED; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION MEDIATORS; LACTOYLGLUTATHIONE LYASE; LIPOPROTEINS, LDL; MACROPHAGES; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; STREPTOZOCIN; UP-REGULATION;

EID: 84913541796     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu189     Document Type: Article

References (42)

1. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly.NEngl J Med 1997; 336:1276-1282
2. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation 1995;92:1701-1709
3. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006;47:C13-C18
4. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstrom P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-2711
5. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in Diabetes. Cardiovasc Res 2004; 63:582-592
6. Hanssen NM, Wouters K, Huijberts MS, Gijbels MJ, Sluimer JC, Scheijen JL, Heeneman S, Biessen EA, Daemen MJ, Brownlee M, de Kleijn DP, Stehouwer CD, Pasterkamp G, Schalkwijk CG. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J 2014;35:1137-1146
7. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597-605
8. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ. Advanced glycation end product interventions reduce diabetes-Accelerated atherosclerosis. Diabetes 2004;53: 1813-1823
9. Watson AM, Soro-Paavonen A, Sheehy K, Li J, Calkin AC, Koitka A, Rajan SN, Brasacchio D, Allen TJ, Cooper ME, Thomas MC, Jandeleit-Dahm KJ. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-Accelerated atherosclerosis in Diabetic apolipoprotein E knockout mice. Diabetologia 2011;54:681-689
10. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820
11. Ewaschuk JB, Naylor JM, Zello GA. D-lactate in human and ruminant metabolism. J Nutr 2005;135:1619-1625
12. Brouwers O, Niessen PM, Miyata T, Ostergaard JA, Flyvbjerg A, Peutz-Kootstra CJ, Sieber J, Mundel PH, Brownlee M, Janssen BJ, De Mey JG, Stehouwer CD, Schalkwijk CG. Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia 2014;57: 224-235
13. Berner AK, Brouwers O, Pringle R, Klaassen I, Colhoun L, McVicar C, Brockbank S, Curry JW, Miyata T, Brownlee M, Schlingemann RO, Schalkwijk C, Stitt AW. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 2012;55:845-854
14. Brouwers O, Niessen PM, Haenen G, Miyata T, Brownlee M, Stehouwer CD, De Mey JG, Schalkwijk CG. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 2010;53:989-1000
15. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, N1-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982-9986
16. Inagi R, Miyata T, Ueda Y, Yoshino A, Nangaku M, van Ypersele de Strihou C, Kurokawa K. Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid. Kidney Int 2002;62:679-687
17. Scheijen JL, Schalkwijk CG. Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultraperformance liquid chromatography tandem mass spectrometry: evaluation of blood specimen. Clin Chem Lab Med 2013; 52:1-7
18. Hanssen NM, Engelen L, Ferreira I, Scheijen JL, Huijberts MS, van Greevenbroek MM, van Der Kallen CJ, Dekker JM, Nijpels G, Stehouwer CD, Schalkwijk CG. Plasma levels of advanced glycation endproducts Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies. J Clin Endocrinol Metab 2013;98:E1369-E1373
19. Deguchi JO, Aikawa E, Libby P, Vachon JR, Inada M, Krane SM, Whittaker P, Aikawa M. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 2005;112:2708-2715
20. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, Fijneman RJ, Clausen BE, Forster I, Kockx MM, Rajewsky K, Kraal G, Hofker MH, de Winther MP. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003;112:1176-1185
21. McLellan AC, Thornalley PJ. Glyoxalase activity in human red blood cells fractioned by age. Mech Ageing Dev 1989;48:63-71
22. Cudejko C, Wouters K, Fuentes L, Hannou SA, Paquet C, Bantubungi K, Bouchaert E, Vanhoutte J, Fleury S, Remy P, Tailleux A, Chinetti-Gbaguidi G, Dombrowicz D, Staels B, Paumelle R. p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. Blood 2011;118:2556-2566
23. Crauwels HM, Van Hove CE, Holvoet P, Herman AG, Bult H. Plaque-Associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. Effect of human apolipoprotein AI. Cardiovasc Res 2003;59:189-199
24. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP. Diabetes-Associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001;50:2792-2808
25. Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, Teerlink T, Schrauwen P, Brownlee M, Stehouwer CD, Schalkwijk CG. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in Diabetic rats. J Biol Chem 2011;286:1374-1380
26. Giacco F, Du X, DAgati VD, Milne R, Sui G, Geoffrion M, Brownlee M. Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes 2014;63: 291-299
27. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, Eberhardt M, Schnolzer M, Lasitschka F, Neuhuber WL, Kichko TI, Konrade I, Elvert R, Mier W, Pirags V, Lukic IK, Morcos M, Dehmer T, Rabbani N, Thornalley PJ, Edelstein D, Nau C, Forbes J, Humpert PM, Schwaninger M, Ziegler D, Stern DM, Cooper ME, Haberkorn U, Brownlee M, Reeh PW, Nawroth PP. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in Diabetic neuropathy. Nat Med 2012;18:926-933
28. Vulesevic B, McNeill B, Geoffrion M, Kuraitis D, McBane JE, Lochhead M, Vanderhyden BC, Korbutt GS, Milne RW, Suuronen EJ. Glyoxalase-1 overexpression in bone marrow cells reverses defective neovascularization in STZ-induced diabetic mice. Cardiovasc Res 2014;101:306-316
29. Geoffrion M, Du X, Irshad Z, Vanderhyden BC, Courville K, Sui G, DAgati VD, Ott-Braschi S, Rabbani N, Thornalley PJ, Brownlee M, Milne RW. Differential effects of glyoxalase 1 overexpression on Diabetic atherosclerosis and renal dysfunction in streptozotocin-Treated, apolipoprotein E-deficient mice. Physiol Rep 2014;2:pii:e12043
30. Staniszewska MM, Nagaraj RH. Upregulation of glyoxalase I fails to normalize methylglyoxal levels: a possible mechanism for biochemical changes in Diabetic mouse lenses. Mol Cell Biochem 2006;288:29-36
31. Esterbauer H. Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 1993;57:779S-785S; discussion 785S-786S.
32. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006;26:2716-2723
33. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-Analysis of randomised controlled trials. BMJ 2011;343:d4169
34. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003;91:7A-11A.
35. Birkenmeier G, Stegemann C, Hoffmann R, Gunther R, Huse K, Birkemeyer C. Posttranslational modification of human glyoxalase 1 indicates redox-dependent regulation. PLoS ONE 2010;5:e10399
36. Mitsumoto A, Kim KR, Oshima G, Kunimoto M, Okawa K, Iwamatsu A, Nakagawa Y. Nitric oxide inactivates glyoxalase I in cooperation with glutathione. J Biochem 2000; 128:647-654
37. Honek JF. Bacterial glyoxalase I enzymes: structural and biochemical investigations. Biochem Soc Trans 2014;42:479-484
38. Yadav SK, Singla-Pareek SL, Sopory SK. An overview on the role of methylglyoxal and glyoxalases in plants. Drug Metabol Drug Interact 2008;23:51-68
39. Tikellis C, Pickering RJ, Tsorotes D, Huet O, Cooper ME, Jandeleit-Dahm K, Thomas MC. Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in Diabetes. Diabetes 2014; in Press
40. Baba SP, Barski OA, Ahmed Y, OToole TE, Conklin DJ, Bhatnagar A, Srivastava S. Reductive metabolism ofAGEprecursors: a metabolic route for preventingAGEaccumulation in cardiovascular tissue. Diabetes 2009;58:2486-2497
41. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, Ramasamy R, Yan SF, Schmidt AM. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE2/2 mice. J Clin Invest 2008;118:183-194
42. Schmidt AM, Yan SD, Yan SF, Stern DM.The multiligand receptorRAGEas a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-955